课题基金 / 基金详情

Development of Innovative Human Stromal Invasion Assay

Development of Innovative Human Stromal Invasion Assay
创新型人类基质侵袭试验的开发
批准号:
6993325
负责人:
B LYNN ALLEN-HOFFMANN
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-29 至 2007-02-28

项目摘要

项目成果

B LYNN ALLEN-HOFFMANN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The ultimate goal of this STTR proposal is to develop an innovative human tumor invasion assay for use as a screening tool in the identification of new anti-tumor therapeutics. Development of a model of early stage tumor invasion, the precursor condition to metastasis, coupled with a highly sensitive readout, is needed to identify new targets for drugs and/or agents that can be used to abrogate the invasion of primary H&N tumors and other types of carcinoma in humans. The NIKS(tm)-based human tumor model developed in the Allen-Hoffmann laboratory permits monitoring tumor cell growth within a normally developed, stratified squamous epithelium. Multiphoton imaging, an important tool for nondestructive investigation of living tissues, provides a highly sensitive readout for the detection of early changes in stroma underlying and/or surrounding tumors. We propose to expand upon our existing NIKS(tm)-NTM model by incorporating human tumor cells that possess a genetically engineered, invasive phenotype, and monitoring the behavior of these cells using multiphoton imaging. The following specific aims will be accomplished during Phase I: (1) Design and construct MT1-MMP expression vector, and demonstrate elevated MT1-MMP mRNA expression levels in transiently-transfected SCC13y cell monolayer cultures, (2) Demonstrate elevated protein expression levels and bioactivity in transiently-transfected SCC13y cell monolayer cultures, and (3) Develop stable, genetically-modified SCC13y cell clones, and evaluate bioactivity of these stable clones utilizing multiphoton microscopy. The unique combination of the novel stromal invasion model with a sophisticated imaging based readout will provide the pharmaceutical industry with a biologically relevant, human cell based, high throughput screening tool to evaluate novel cytostatic agents, and/or gene therapy strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Innovative Bioengineering for Cutaneous Wounds
  • 批准号:
    7016322
  • 项目类别:
  • 资助金额:
    $35.01万
  • 财政年份:
    2005
  • 负责人:
    B LYNN ALLEN-HOFFMANN
  • 依托单位:
Innovative Bioengineering for Cutaneous Wounds
  • 批准号:
    7394448
  • 项目类别:
  • 资助金额:
    $33.45万
  • 财政年份:
    2005
  • 负责人:
    B LYNN ALLEN-HOFFMANN
  • 依托单位:
Innovative Bioengineering for Cutaneous Wounds
  • 批准号:
    6928052
  • 项目类别:
  • 资助金额:
    $35.61万
  • 财政年份:
    2005
  • 负责人:
    B LYNN ALLEN-HOFFMANN
  • 依托单位:
Innovative Bioengineering for Cutaneous Wounds
  • 批准号:
    7255618
  • 项目类别:
  • 资助金额:
    $33.45万
  • 财政年份:
    2005
  • 负责人:
    B LYNN ALLEN-HOFFMANN
  • 依托单位:
国内基金
海外基金
ITS-HPLC-HRMS-Bioassay多级筛选策略指导下海洋真菌中新型抗菌活性产物的发现